|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Hookipa Pharma Inc. (HOOK) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
50,880,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile HOOKIPA Pharma is a biopharmaceutical company developing a class of immunotherapeutics based on its proprietary arenavirus platform that is designed to target and amplify a T cell and immune response to disease. Co. is building a proprietary immuno-oncology pipeline by targeting oncoviral cancer antigens, self-antigens and antigens. Co.'s lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papillomavirus 16-positive cancers in a Phase 1/2 clinical trial. Co.'s non-replicating prophylactic Cytomegalovirus vaccine candidate, HB-101, is a potential compound in a Phase 2 clinical trial for kidney transplant patients.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
47,000 |
47,000 |
Total Buy Value |
$0 |
$0 |
$38,445 |
$38,445 |
Total People Bought |
0 |
0 |
2 |
2 |
Total Buy Transactions |
0 |
0 |
7 |
7 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Orlinger Klaus |
Sr. VP, Research |
|
2020-01-14 |
4 |
OE |
$0.10 |
$850 |
D/D |
8,500 |
8,500 |
|
- |
|
Matushansky Igor |
Chief Medical Officer |
|
2019-12-19 |
4 |
S |
$9.93 |
$103,312 |
D/D |
(10,404) |
58,898 |
|
- |
|
Matushansky Igor |
Chief Medical Officer |
|
2019-12-19 |
4 |
OE |
$0.10 |
$2,589 |
D/D |
25,891 |
69,302 |
|
- |
|
Matushansky Igor |
Chief Medical Officer |
|
2019-12-17 |
4 |
S |
$7.87 |
$90,379 |
D/D |
(11,484) |
43,411 |
|
- |
|
Matushansky Igor |
Chief Medical Officer |
|
2019-12-17 |
4 |
OE |
$0.10 |
$2,631 |
D/D |
26,312 |
54,895 |
|
- |
|
Sofinnova Partners Sas |
10% Owner |
|
2019-04-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
82,456 |
|
- |
|
Pinschewer David |
Chief Scientific OfficerOffice |
|
2019-04-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
165,773 |
|
- |
|
Forbion Capital Fund Ii Cooperatief U.a. |
10% Owner |
|
2019-04-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
9,314 |
|
- |
|
Matushansky Igor |
Chief Medical OfficerOfficer |
|
2019-04-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
28,583 |
|
- |
|
59 Records found
|
|
Page 3 of 3 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|